An in vivo evaluation of anti-inflammatory, analgesic and anti-pyretic activities of newly synthesized 1, 2, 4 Triazole derivatives.
1, 2, 4-Triazoles
Anti-inflammatory
Anti-nociceptive
Anti-pyretic
Paw edema
Post-operative pain
Journal
BMC complementary medicine and therapies
ISSN: 2662-7671
Titre abrégé: BMC Complement Med Ther
Pays: England
ID NLM: 101761232
Informations de publication
Date de publication:
31 Dec 2021
31 Dec 2021
Historique:
received:
06
04
2021
accepted:
09
12
2021
entrez:
1
1
2022
pubmed:
2
1
2022
medline:
11
1
2022
Statut:
epublish
Résumé
In recent years, 1, 2, 4-triazole and its derivatives have been reported to be pharmacologically significant scaffolds. They possess analgesic, anti-tubercular, anti-inflammatory, anti-convulsant, anti-oxidant, anti-fungal, anti-cancer, anxiolytic and anti-depressant activity. This study was designed and conducted to evaluate the potential anti-inflammatory, analgesic and antipyretic activities of Triazole derivatives. Swiss albino (male and female) mice weighing 20-30 g (10-24 weeks female), (5-14 weeks male) and Wister Kyoto rats (male and female) weighing 200-300 g (8-10 weeks old) were used for the present study. Anti-inflammatory activity was checked using Lambda carrageenan (λ) and egg albumin-induced paw edema models. Analgesic via Writhing Reflex induced by acetic acid and formalin, furthermore anti-pyretic activity was assessed by yeast induced pyrexia. Both of the test compounds exhibited encouraging anti-inflammatory analgesic and antipyretic results when compared with standard drug ibuprofen. The maximum inhibition of edema for the compound (S)-1-(4-Amino-5-mercapto-4H-1,2,4-triazole-3-yl) ethanol [3] was found to be (91)% as compared to reference drug ibuprofen (82)%, while (S)-1-(6-Phenyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazin-3-yl)ethanol [5e] showed equipotent results to ibuprofen (81)%. The derivatives were also screened for their anti-nociceptive activity by Acetic acid writhing and tail immersion test. Compound 3 showed a significant reduction in wriths (83)% as compared to standard drug ibuprofen 71.5% and [5] showed comparable results to ibuprofen by exhibiting 70% reduction in writh at the same dose as that of standard drug, moreover, there were no signs of toxicity being observed after administration of high doses of test compounds to mice. It is evident from the results that compounds 3(compound A) and 5(compound B) are a potential candidate for anti-inflammatory, analgesic and anti-pyretic and the scaffold could be used for further structural modifications. Further studies would help to evaluate their molecular mechanism of action regarding these beneficial activities.
Sections du résumé
BACKGROUND
BACKGROUND
In recent years, 1, 2, 4-triazole and its derivatives have been reported to be pharmacologically significant scaffolds. They possess analgesic, anti-tubercular, anti-inflammatory, anti-convulsant, anti-oxidant, anti-fungal, anti-cancer, anxiolytic and anti-depressant activity. This study was designed and conducted to evaluate the potential anti-inflammatory, analgesic and antipyretic activities of Triazole derivatives.
METHODS
METHODS
Swiss albino (male and female) mice weighing 20-30 g (10-24 weeks female), (5-14 weeks male) and Wister Kyoto rats (male and female) weighing 200-300 g (8-10 weeks old) were used for the present study. Anti-inflammatory activity was checked using Lambda carrageenan (λ) and egg albumin-induced paw edema models. Analgesic via Writhing Reflex induced by acetic acid and formalin, furthermore anti-pyretic activity was assessed by yeast induced pyrexia.
RESULTS
RESULTS
Both of the test compounds exhibited encouraging anti-inflammatory analgesic and antipyretic results when compared with standard drug ibuprofen. The maximum inhibition of edema for the compound (S)-1-(4-Amino-5-mercapto-4H-1,2,4-triazole-3-yl) ethanol [3] was found to be (91)% as compared to reference drug ibuprofen (82)%, while (S)-1-(6-Phenyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazin-3-yl)ethanol [5e] showed equipotent results to ibuprofen (81)%. The derivatives were also screened for their anti-nociceptive activity by Acetic acid writhing and tail immersion test. Compound 3 showed a significant reduction in wriths (83)% as compared to standard drug ibuprofen 71.5% and [5] showed comparable results to ibuprofen by exhibiting 70% reduction in writh at the same dose as that of standard drug, moreover, there were no signs of toxicity being observed after administration of high doses of test compounds to mice.
CONCLUSIONS
CONCLUSIONS
It is evident from the results that compounds 3(compound A) and 5(compound B) are a potential candidate for anti-inflammatory, analgesic and anti-pyretic and the scaffold could be used for further structural modifications. Further studies would help to evaluate their molecular mechanism of action regarding these beneficial activities.
Identifiants
pubmed: 34972515
doi: 10.1186/s12906-021-03485-x
pii: 10.1186/s12906-021-03485-x
pmc: PMC8720215
doi:
Substances chimiques
Analgesics
0
Anti-Inflammatory Agents
0
Antipyretics
0
Triazoles
0
1,2,4-triazole
288-88-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
304Informations de copyright
© 2021. The Author(s).
Références
Drugs Today (Barc). 2015 Dec;51(12):705-18
pubmed: 26798851
J Pharm Bioallied Sci. 2011 Apr;3(2):259-65
pubmed: 21687356
J Neurosci Methods. 2005 Aug 30;147(1):29-35
pubmed: 16054514
Bioorg Med Chem. 2008 Aug 15;16(16):7804-10
pubmed: 18657979
Front Biosci. 2004 May 01;9:1977-93
pubmed: 14977603
Braz J Med Biol Res. 2003 Jan;36(1):119-23
pubmed: 12532235
Mater Sociomed. 2016 Feb;28(1):36-40
pubmed: 27047265
Pak J Pharm Sci. 2009 Oct;22(4):395-401
pubmed: 19783518
J Med Chem. 2010 May 27;53(10):4248-58
pubmed: 20420439
Pain. 1992 Oct;51(1):5-17
pubmed: 1454405
J Pharm Pharmacol. 1996 Mar;48(3):327-31
pubmed: 8737064
Peptides. 2012 Sep;37(1):165-70
pubmed: 22732665
Neuropharmacology. 1976 Nov;15(11):683-8
pubmed: 12485
J Biomol Struct Dyn. 2021 Feb;39(2):457-475
pubmed: 31900051
Bioorg Chem. 2017 Dec;75:242-259
pubmed: 29032325
Eur J Med Chem. 2020 Mar 15;190:112114
pubmed: 32061962
CNS Spectr. 2008 Jun;13(6):501-10
pubmed: 18567974
Eur J Med Chem. 2010 Jan;45(1):63-8
pubmed: 19939519
Eur J Med Chem. 2009 Nov;44(11):4752-7
pubmed: 19616347
J Pharm Pharmacol. 1968 Apr;20(4):305-12
pubmed: 4384610
Asian Pac J Trop Med. 2012 Jan;5(1):62-6
pubmed: 22182646
Inflamm Res. 2010 Mar;59(3):189-96
pubmed: 19730987
J Pharm Pharm Sci. 2005 Apr 20;8(1):102-6
pubmed: 15946603
Afr J Tradit Complement Altern Med. 2009 Jul 03;6(4):529-33
pubmed: 20606773
Bioorg Med Chem Lett. 2016 Aug 1;26(15):3632-5
pubmed: 27289320
J Pharmacol Exp Ther. 2011 Nov;339(2):537-44
pubmed: 21816956
Eur J Med Chem. 2020 Nov 1;205:112652
pubmed: 32771798
Nature. 2008 Jul 24;454(7203):428-35
pubmed: 18650913
Rev Biol Trop. 2009 Dec;57(4):1193-200
pubmed: 20073344
Neurosci Biobehav Rev. 2000 May;24(3):375-89
pubmed: 10781697
Adv Pharmacol Sci. 2012;2012:862625
pubmed: 22235200
Eur J Med Chem. 2009 Nov;44(11):4637-47
pubmed: 19647905
J Diet Suppl. 2012 Sep;9(3):155-65
pubmed: 22877413
Arch Pharm (Weinheim). 2017 Jul;350(7):
pubmed: 28594090
J Ethnopharmacol. 2008 Feb 28;116(1):187-90
pubmed: 18079077
Nature. 2001 Sep 13;413(6852):203-10
pubmed: 11557989
Eur J Med Chem. 2012 Nov;57:398-406
pubmed: 22840494
J Basic Clin Physiol Pharmacol. 2014 May 1;25(2):175-80
pubmed: 23893681
Eur J Med Chem. 2003 Jul-Aug;38(7-8):759-67
pubmed: 12932907
Arch Pharm (Weinheim). 2018 Apr;351(3-4):e1700304
pubmed: 29611883
Bioorg Med Chem. 2011 Oct 15;19(20):5948-54
pubmed: 21925884
Curr Med Chem. 2012;19(2):239-80
pubmed: 22320301
Bioorg Med Chem. 2015 May 15;23(10):2518-28
pubmed: 25868745
J Pharm Bioallied Sci. 2010 Apr;2(2):109-12
pubmed: 21814442
J Ethnopharmacol. 2011 Mar 24;134(2):251-8
pubmed: 21167270
Pain Res Manag. 2018 Jul 4;2018:4838413
pubmed: 30073041
Front Mol Neurosci. 2017 Sep 06;10:284
pubmed: 28932184
Pharm Biol. 2017 Dec;55(1):898-905
pubmed: 28147891